This phase I/II trial is evaluating the safety and activity of a new oral treatment (FLX475) alone and in combination with immunotherapy (Pembrolizumab) in patients with advanced cancer.
This trial is treating multiple types of cancer including non-small cell lung cancer, head and neck squamous cell carcinoma,cancer of the nose, metastatic triple negative breast cancer, urothelial carcinoma, gastric cancer, oesophageal cancer, cervical cancer or Hodgkin lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
RAPT Therapeutics, Inc.
This is a non-randomised, dose escalation and expansion study in which patients will receive either FLX475 as a monotherapy or in combination with Pembrolizumab at escalating or defined doses. In Part 1 of the study, subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 as monotherapy or in combination with pembrolizumab. In Part 2 of the study, subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 as monotherapy or in combination with pembrolizumab.
Recruiting Hospitals Read More